deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02451553

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Sponsor: University of Washington

Conditions Advanced Malignant Solid Neoplasm Bile Duct Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IVA Pancreatic Cancer Stage IVB Pancreatic Cancer
Interventions Afatinib Dimaleate Capecitabine Laboratory Biomarker Analysis
Updated 19 times since 2017 Last updated: Jun 3, 2022 Started: Nov 5, 2015 Primary completion: Apr 16, 2022 Completion: Apr 16, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Malignant Solid Neoplasm and Bile Duct Carcinoma, this trial is completed. The trial is conducted by University of Washington and has accumulated 19 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Sep 2017 · 6 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Oct 2021 · 6 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 14 earlier versions

  1. Oct 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  2. Apr 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  3. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  5. Nov 2019 — Oct 2020 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  6. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  7. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  8. Jan 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  9. Aug 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  11. Sep 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Mar 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Washington
Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations